Haemonetics CORP Form 4 insider transactions

Director Lloyd Emerson Johnson reports acquiring 2,207 restricted stock units of Haemonetics Corp on July 25, 2024.

Director Mark W. Kroll reports acquisition of 2,207 restricted stock units in Haemonetics Corp.

Director Claire Pomeroy reported the acquisition of 2,207 restricted stock units (RSUs) of Haemonetics Corp on July 25, 2024.

Director Ellen M. Zane acquired 2,207 restricted stock units of Haemonetics Corp on July 25, 2024.

Anila Lingamneni, EVP and Chief Technology Officer of Haemonetics Corp, reported the sale of company stock on July 11 and 12, 2024, according to a Form 4 filing with the SEC.

Christopher Simon, President & CEO of Haemonetics Corp, exercised stock options and disposed of shares to cover tax obligations on June 6, 2024.

Anila Lingamneni, EVP and Chief Technology Officer of Haemonetics, reports acquisition of shares from a performance share unit award and disposition of shares for tax obligations.

Josep Llorens, EVP of Global Manufacturing at Haemonetics Corp, reports acquisition of shares from a performance share unit award and disposition of shares for tax obligations.

Michelle Basil, EVP and General Counsel of Haemonetics, reports the acquisition and disposal of company stock, including shares from a performance share unit award and sales under a 10b5-1 trading plan.

Laurie A. Miller, SVP of Human Resources at Haemonetics Corp, reports acquisition of shares from performance share units and disposition of shares for tax obligations.

Christopher Simon, President & CEO of Haemonetics Corp, reports acquisition of shares from a performance share unit award and subsequent withholding of shares for tax obligations.

Stewart W. Strong, President of Global Hospital at Haemonetics Corp, reports acquisition and disposal of company stock, including shares from performance share units and sales under a 10b5-1 trading plan.

Maryanne Farris Maunsell, VP, Chief Accounting Officer of Haemonetics Corp, reports the acquisition of restricted stock units and stock options.

Stewart W. Strong, President of Global Hospital at Haemonetics Corp, reports multiple transactions involving common stock and stock options, including acquisitions, disposals, and exercises, under a pre-existing 10b5-1 trading plan.

Laurie A. Miller, SVP of Human Resources at Haemonetics Corp, reports the acquisition and disposal of company stock and stock options.

Anila Lingamneni, EVP and Chief Technology Officer of Haemonetics, reports the acquisition and disposal of company stock and stock options.

Josep Llorens, EVP of Global Manufacturing at Haemonetics, reports the acquisition and disposal of company stock, including transactions under a 10b5-1 trading plan and vesting of restricted stock units.

Roy Galvin, President of Global Plasma & BC at Haemonetics Corp, reports the acquisition of common stock and stock options.

Michelle Basil, EVP and General Counsel of Haemonetics, reports multiple transactions involving common stock, including sales, acquisitions, and tax-related withholdings, as well as the acquisition of non-qualified stock options.

James D'Arecca, EVP and CFO of Haemonetics, reports the acquisition of common stock and stock options.

Christopher Simon, President & CEO of Haemonetics Corp, reports acquisition and disposal of company stock and stock options.

Stewart W. Strong, President, Global Hospital at Haemonetics Corp, reports stock transactions including sales and option exercises on May 15 and 16, 2024.

Roy Galvin, President, Global Plasma & BC at Haemonetics Corp, reports disposition of shares to cover tax obligations and acquisition of shares through an employee stock purchase plan.

Maryanne Maunsell Farris, VP and Chief Accounting Officer of Haemonetics Corp, reports a transaction involving the withholding of shares for tax obligations related to vesting restricted stock units.

Michelle Basil, EVP and General Counsel of Haemonetics, reports the withholding of shares for tax obligations and a sale of shares under a pre-arranged 10b5-1 trading plan.

Laurie A. Miller, SVP of Human Resources at Haemonetics Corp, reports disposing of shares to cover tax obligations related to vesting restricted stock units.

Josep Llorens, EVP of Global Manufacturing at Haemonetics, reports the disposition and acquisition of company stock, including shares withheld for tax obligations and sales under a 10b5-1 trading plan.

James D'Arecca, EVP and Chief Financial Officer of Haemonetics, reported disposing of shares to cover tax obligations related to vesting restricted stock units.

Christopher Simon, President & CEO of Haemonetics Corp, reports the disposal of shares to cover tax obligations and an acquisition through the employee stock purchase plan.

Anila Lingamneni, EVP and Chief Technology Officer of Haemonetics Corp, reports disposals of common stock to cover tax obligations related to vesting restricted stock units.